Paolo Dapavo

3.0k total citations
82 papers, 938 citations indexed

About

Paolo Dapavo is a scholar working on Dermatology, Immunology and Physiology. According to data from OpenAlex, Paolo Dapavo has authored 82 papers receiving a total of 938 indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Dermatology, 51 papers in Immunology and 21 papers in Physiology. Recurrent topics in Paolo Dapavo's work include Psoriasis: Treatment and Pathogenesis (49 papers), Dermatology and Skin Diseases (38 papers) and Asthma and respiratory diseases (19 papers). Paolo Dapavo is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (49 papers), Dermatology and Skin Diseases (38 papers) and Asthma and respiratory diseases (19 papers). Paolo Dapavo collaborates with scholars based in Italy, Belarus and United States. Paolo Dapavo's co-authors include Pietro Quaglino, Simone Ribero, Luca Mastorino, Michela Ortoncelli, Niccolò Siliquini, Gianluca Avallone, Maria Teresa Fierro, Paolo Gisondi, Piergiorgio Malagoli and Anna Verrone and has published in prestigious journals such as The Journal of Immunology, Journal of the American Academy of Dermatology and Autoimmunity Reviews.

In The Last Decade

Paolo Dapavo

69 papers receiving 928 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paolo Dapavo Italy	19	588	532	199	179	162	82	938
Martina Burlando Italy	16	460 0.8×	357 0.7×	252 1.3×	111 0.6×	227 1.4×	96	859
J.M.P.A. van den Reek Netherlands	20	785 1.3×	470 0.9×	217 1.1×	186 1.0×	98 0.6×	41	1.1k
Ziqian Geng United States	9	706 1.2×	552 1.0×	137 0.7×	135 0.8×	108 0.7×	14	1.1k
T.N. Dam Denmark	14	753 1.3×	462 0.9×	145 0.7×	126 0.7×	119 0.7×	21	1.0k
Scott Fretzin United States	10	820 1.4×	474 0.9×	303 1.5×	164 0.9×	128 0.8×	14	1.0k
Fabrizio Martora Italy	17	365 0.6×	568 1.1×	72 0.4×	62 0.3×	156 1.0×	85	836
Isabelle Hampele United States	6	1.3k 2.3×	751 1.4×	344 1.7×	256 1.4×	261 1.6×	8	1.6k
Sophie Hugot Switzerland	9	1.0k 1.7×	577 1.1×	378 1.9×	140 0.8×	221 1.4×	10	1.3k
Nikolai Loft Denmark	18	559 1.0×	516 1.0×	228 1.1×	182 1.0×	76 0.5×	51	1.0k
M. Tauber France	16	319 0.5×	419 0.8×	156 0.8×	155 0.9×	60 0.4×	63	837

Countries citing papers authored by Paolo Dapavo

Since Specialization

Citations

This map shows the geographic impact of Paolo Dapavo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paolo Dapavo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paolo Dapavo more than expected).

Fields of papers citing papers by Paolo Dapavo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paolo Dapavo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paolo Dapavo. The network helps show where Paolo Dapavo may publish in the future.

Co-authorship network of co-authors of Paolo Dapavo

This figure shows the co-authorship network connecting the top 25 collaborators of Paolo Dapavo. A scholar is included among the top collaborators of Paolo Dapavo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paolo Dapavo. Paolo Dapavo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marzano, Angelo Valerio, Michele Bartoletti, Vincenzo Bettoli, et al.. (2025). Hidradenitis suppurativa, from basic science to surgery and a new era of tailored targeted therapy: An expert opinion paper. Archives of Dermatological Research. 317(1). 511–511. 1 indexed citations

Valenti, Mario, Luciano Ibba, S. Di Giulio, et al.. (2025). Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis). Journal of Dermatological Treatment. 36(1). 2456532–2456532.

Mastorino, Luca, Paolo Dapavo, Michela Ortoncelli, et al.. (2025). Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years. Clinical and Experimental Dermatology. 51(1). 35–41.

Mastorino, Luca, Paolo Dapavo, Michela Ortoncelli, et al.. (2025). Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing. Experimental Dermatology. 34(2). e70062–e70062. 2 indexed citations

Mastorino, Luca, Paolo Dapavo, Martina Burlando, et al.. (2025). Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years. PubMed. Volume 15. 339–350.

Roccuzzo, Gabriele, et al.. (2024). Anti‐IL17 Secukinumab in hidradenitis suppurativa: A long‐term drug survival analysis. Experimental Dermatology. 33(7). e15140–e15140. 3 indexed citations

Mastorino, Luca, Caterina Cariti, Niccolò Siliquini, et al.. (2023). Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study. Dermatologic Therapy. 2023(1). 2 indexed citations

Mastorino, Luca, Paolo Dapavo, Francesco Leo, et al.. (2023). Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years. Journal of the European Academy of Dermatology and Venereology. 38(3). 568–575. 11 indexed citations

Bellinato, Francesco, Paolo Gisondi, Angelo Valerio Marzano, et al.. (2023). Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study. Vaccines. 11(4). 740–740. 7 indexed citations

10.

Avallone, Gianluca, Carlo Alberto Maronese, Carlo Giovanni Carrera, et al.. (2023). Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study. Journal of Clinical Medicine. 12(4). 1662–1662. 20 indexed citations

11.

Mastorino, Luca, et al.. (2023). Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study. Journal of Clinical Medicine. 12(23). 7215–7215. 6 indexed citations

12.

Giordano, Silvia, Paolo Dapavo, Michela Ortoncelli, et al.. (2023). Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience. Journal of Clinical Medicine. 12(24). 7503–7503. 7 indexed citations

13.

Roccuzzo, Gabriele, et al.. (2023). Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study. Acta Dermato Venereologica. 103. adv5278–adv5278. 8 indexed citations

14.

Gallo, Giuseppe, Luca Mastorino, Francesco Cattel, et al.. (2022). Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis. Dermatologic Therapy. 35(12). e15917–e15917. 3 indexed citations

15.

Mastorino, Luca, Niccolò Siliquini, Gianluca Avallone, et al.. (2022). Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis. Dermatology Reports. 14(3). 9282–9282. 5 indexed citations

16.

Malagoli, Piergiorgio, Paolo Dapavo, Giulia Pavia, et al.. (2022). Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study— IL PSO ( Italian landscape psoriasis). Dermatologic Therapy. 35(8). e15608–e15608. 10 indexed citations

17.

Ribero, Simone, et al.. (2021). Brodalumab treatment in psoriasis patients with severe renal failure. Italian Journal of Dermatology and Venereology. 156(3). 406–408. 1 indexed citations

18.

Ribero, Simone, Gabriella Fabbrocini, Vincenzo Bettoli, et al.. (2021). Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting. Journal of the European Academy of Dermatology and Venereology. 35(7). e441–e442. 39 indexed citations

19.

Marzano, Angelo Valerio, Andrea Chiricozzi, Giuseppe Argenziano, et al.. (2020). Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: the HIDRAscore. Journal of the European Academy of Dermatology and Venereology. 34(8). 1815–1821. 12 indexed citations

20.

Marzano, Angelo Valerio, Giovanni Genovese, Giovanni Casazza, et al.. (2018). Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. Journal of the European Academy of Dermatology and Venereology. 33(5). 918–924. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact